http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0415920-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5135e1534b07d32fbfe49746aad3ca3c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-809 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1054 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 1988-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35fa3f09d7ef861910bf6c85f43bfdef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af5cf5d61bcc2288c7181700913e17d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2e0a9293b3b542df0b5d0a10c0d41cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4465fd5a8397c6d0da06077951ad2866 |
| publicationDate | 1991-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0415920-A1 |
| titleOfInvention | AGAINST HIV-ANTIGENT SPECIFIC MONOCLONAL ANTIBODIES. |
| abstract | The hybrid cell line described has the power to produce monoclonal antibodies which bind to the P55 antigen of the HIV (human immunodeficiency virus) nucleus, to the precursor protein coded for the gag gene, to the core protein P24 and to partial disruption products of types P39 and P33. The monoclonal antibody of the present invention does not bind to the P18 nucleus protein or to the HIV envelope antigens. The cell line of the present invention was developed by a unique immunization protocol, in which BALB / c type mice were immunized in a series of several injections using a selected group of immunogens and a traditional myeloma cell line for fusion with cultured murine splenocytes. Said monoclonal antibody is identified as the KC-57 antibody. This monoclonal antibody is particularly useful for solid phase immunoassay, in which the monoclonal antibody is detected in its binding to HIV antigens found in a serum or plasma sample from a human subject. The cell line which produces the monoclonal antibody KC-57 has been registered with the American Type Culture Collection in Rockville, Maryland and received by A.T.C.C. HB 9585. |
| priorityDate | 1987-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 208.